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Mechanistic target of Rapamycin (mTOR) pathway regulates essential processes directed
to preserve cellular homeostasis, such as cell growth, proliferation, survival, protein
synthesis and autophagy. Importantly, mTOR pathway deregulation has been related
to many diseases. Indeed, it has become a hallmark in neurodegenerative disorders,
since a fine-tuned regulation of mTOR activities is crucial for neuron function and
survival. RTP801/REDD1/Dig2 has become one of the most puzzling regulators of mTOR.
Although the mechanism is not completely understood, RTP801 inactivates mTOR and
Akt via the tuberous sclerosis complex (TSC1/TSC2) in many cellular contexts. Intriguingly,
RTP801 protects dividing cells from hypoxia or H2O2-induced apoptosis, while it sensitizes
differentiated cells to stress. Based on experimental models of Parkinson’s disease (PD), it
has been proposed that at early stages of the disease, stress-induced RTP801 upregulation
contributes to mTOR repression, in an attempt to maintain cell function and viability.
However, if RTP801 elevation is sustained, it leads to neuron cell death by a sequential
inhibition of mTOR and Akt. Here, we will review RTP801 deregulation of mTOR in a
context of PD and other neurodegenerative disorders.
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RTP801 OVERVIEW
RTP801 (also known as REDD1 or Dig2) is a protein encoded
by the stress responsive gene DNA-damage-inducible transcript
4 (DDIT4). It was initially identified and cloned in 2002 by two
different groups simultaneously.
Shoshani et al. (2002) screened for hypoxia-regulated genes in
rat C6 glioma cells and they identified a highly up-regulated gene
responsive to HIF-1, involved in the regulation of cellular reactive
oxygen species (ROS). It was designated RTP801 (Shoshani et al.,
2002).
Concurrently, Ellisen et al. (2002) cloned a gene induced after
DNA damage and during embryogenesis in a p53 and p63 depen-
dent manner. This gene was involved in the regulation of ROS and
was alternatively named REDD1, for regulated in development
and DNA damage responses one (Ellisen et al., 2002).
Later in 2003, Wang et al. discovered Dig2 (for
dexamethasone-induced gene 2), the mouse homolog of
RTP801/REDD1 in an oligonucleotide microarray analysis from
dexamethasone-treated murine lymphoma T cells (Wang et al.,
2003).
Further studies displayed DDIT4 as a rapidly upregulated
gene under multiple cellular stresses, such as heat shock (Wang
et al., 2003), ionizing radiation (Ellisen et al., 2002), hypoxia
(Shoshani et al., 2002; Brugarolas et al., 2004) and energy deple-
tion (Sofer et al., 2005). Moreover other chemical molecules
also upregulated DDIT4 expression, such as dopaminergic
neurotoxins 6-hydroxydopamine, MPTP/MPP+ and rotenone
(Malagelada et al., 2006), endoplasmatic reticulum (ER) stress
inducers tunicamycin and thapsigargin (Wang et al., 2003;
Whitney et al., 2009), DNA damage agent etoposide (Wang et al.,
2003) and arsenite (Lin et al., 2005b).
RTP801, as a 232 aminoacids protein, is ubiquitously expressed
at low levels in numerous human adult tissues (Shoshani et al.,
2002). RTP801 localizes in the cytoplasm, the nucleus (Ellisen
et al., 2002; Lin et al., 2005b; Michel et al., 2014) and in the
membranes (DeYoung et al., 2008; Michel et al., 2014). Besides,
a small fraction of RTP801 was detected in the mitochondria in
HEK293T cells (Horak et al., 2010) and in RGC-5 retinal ganglion
cell line (del Olmo-Aguado et al., 2013).
There is a related human transcript called RTP801L (RTP801-
like) or REDD2 that displays ∼50% sequence identity to RTP801
and has similar functions (Ellisen et al., 2002; Corradetti et al.,
2005).
Besides humans, RTP801 is also present in other organisms
such as rat, mouse and Xenopus. In Drosophila it has two
related orthologs called Scylla and Charybdis (Reiling and Hafen,
2004).
No functional motifs or structural domains could be iden-
tified from RTP801 amino acid sequence analysis and, to date,
the entire crystal structure has not been solved. Indeed, only
one group crystallized a segment containing aminoacids 89–226
with a deletion of the hydrophobic region 200FLPGF204 of the
human RTP801 protein (Vega-Rubin-de-Celis et al., 2010). Their
work has given new insights into RTP801 structure. They found
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that RTP801 presents a unique topology characterized by a
two-layered α/β sandwich with a psi-loop motif. Furthermore, a
surface patch formed by highly conserved residues was found to
be critical for its function. It is formed by two separated regions,
138EPCG141 and 218KKKLYSSE225, that are contiguous in the
three-dimensional structure (Vega-Rubin-de-Celis et al., 2010).
Importantly, the stretch of three lysines 218KKK220 is necessary for
RTP801 to localize in both mitochondria (Horak et al., 2010) and
plasma membrane (Michel et al., 2014).
The key function of RTP801 is its ability to inactivate
mTOR (Brugarolas et al., 2004; Corradetti et al., 2005),
a master regulator kinase that integrates extracellular sig-
nals with intracellular responses to nutrients, growth fac-
tors or stress. Indeed, mTOR regulation has a crucial role
in development, cancer or in neural survival and plas-
ticity (Hoeffer and Klann, 2010; Laplante and Sabatini,
2012).
RTP801 has a dual role depending on the cellular con-
text, meaning that in proliferating non differentiated cells,
RTP801 is anti-apoptotic, and in non-dividing differentiated
cells like neurons, RTP801 is pro-apoptotic (Shoshani et al.,
2002; Malagelada et al., 2006). This dual function could be
nicely observed in a study of rat cortical neurogenesis, where
RTP801 controlled neuroprogenitors proliferation and neuronal
differentiation. In cortical neuroprogenitors RTP801 was ele-
vated without being toxic. On the contrary, newborn and
mature neurons showed lower levels of RTP801. Indeed, if
RTP801 elevation was sustained in these differentiating neu-
rons it became pro-apoptotic (Malagelada et al., 2011). How
RTP801 can trigger these dual actions based on the cell
context is not completely understood and requires further
investigation.
In the last decade the role of mTOR in neural cells has
become very relevant. Indeed, in the nervous system mTOR
controls crucial processes such as protein translation, long-
lasting synaptic plasticity and survival via Akt (Tang et al.,
2002; Cammalleri et al., 2003; Malagelada et al., 2008). Evidence
suggests that mTOR deregulation is involved in neurodegen-
eration, and therefore the role of RTP801 has emerged as an
object of study. In this sense, it will be crucial to understand
the fine balance between RTP801 as a stress-coping protein
and RTP801 as a pro-apoptotic effector in neurological dis-
orders. Understanding these complex mechanisms will help to
design successful therapeutic strategies to halt or, at least, delay
neurodegeneration.
HOW IS RTP801 UPREGULATED?
Previous studies suggest that RTP801 toxicity in neurons is pro-
portional to its protein levels (Malagelada et al., 2010; Ota et al.,
2014). RTP801 protein increase can be the end point of two
different processes: (1) as a result of gene activation by cellular
stress (Ryu et al., 2005; Malagelada et al., 2006); and (2) a defective
RTP801 degradation (Romaní-Aumedes et al., 2014). Here we
will describe the transcription factors responsible for DDIT4 gene
induction, the microRNAs (miRNAs) that regulate its translation
and the post-translational events in charge of regulating RTP801
protein levels.
RTP801 TRANSCRIPTIONAL REGULATION
The variety of transcription factors able to induce DDIT4 gene
expression in response to different stressors illustrates the com-
plexity of its regulation. In fact, one feature of the regulation
of RTP801/DDIT4 is its rapidity, crucial to activate the coping
mechanisms of the cell in response to the hostile environment. For
example, hypoxia upregulates RTP801 expression via HIF-1, since
the DDIT4 gene contains a HRE (hypoxia-response element) in
the promoter (Shoshani et al., 2002; Brugarolas et al., 2004).
Another hypoxia-mimetic agent, cobalt chloride (CoCl2), needs
co-activation of HIF-1 and Sp1 to induce RTP801 (Jin et al.,
2007).
Deoxyribonucleic acid (DNA) damaging agents, including
ionizing radiation and the DNA alkylating agent methyl methane
sulfonate (MMS) also boosted RTP801 expression (Ellisen et al.,
2002; Lin et al., 2005a). Ionizing radiation induced RTP801
in a p53-dependent manner in mouse embryonic fibroblasts
(MEFs; Ellisen et al., 2002). DNA-damage-inducible transcript 4
transcription was also enhanced by MMS in human keratinocytes
via Elk-1 and CCAAT/enhancer-binding protein (C/EBP) in
a p53-independent manner (Lin et al., 2005a). Furthermore,
RTP801 has also been identified as a transcription target of Elk-1
and C/EBP in response to arsenic-induced ROS (Lin et al., 2005b).
Endoplasmatic reticulum (ER) stress caused by tunicamycin
or thapsigargin upregulated RTP801 via activating transcriptional
factor 4 (ATF4; Jin et al., 2009; Whitney et al., 2009). ATF4 was
also identified as a transcription factor for RTP801 in response to
oxidative stress induced by hydrogen peroxide (Jin et al., 2009).
Interestingly, ATF4 has a protective role in cellular models of
Parkinson’s disease (PD) by modulating the levels of the E3 ligase
parkin (Sun et al., 2013).
Other transcription factors have been described for DDIT4
gene regulation like the nuclear factor of activated T-cell c3 (NFAT
c3; Zhou et al., 2012) or PLZF in spermatogonial progenitors
(Hobbs et al., 2010).
It is noteworthy that all these stressors, via different
transcription factors, elevate RTP801 with a common objective
to inactivate mTOR. This common response to stressors corrob-
orates the complexity of the integration of the stress signals to
modulate mTOR effectively.
Many other stress responsive genes with pro-apoptotic
functions are also upregulated in parallel with DDIT4. However,
due to space limitations, they will not be reviewed in this text
(reviewed in Fulda et al., 2010).
RTP801 TRANSLATIONAL REGULATION
MicroRNA are negative regulators of gene expression and can
function as tumor suppressors or oncogenes. To date, at least three
miRNAs have been described as regulators of RTP801/REDD1
expression in a context of tumorigenesis. MiR-495 regulates breast
cancer stem cells proliferation and hypoxia resistance by regulat-
ing RTP801 expression (Hwang-Verslues et al., 2011). Another
miRNA, the miR-221, stimulates hepatocarcinogenesis by down-
regulating RTP801 expression (Pineau et al., 2010). Furthermore,
Micro-RNA30c down-regulates REDD1 expression in human
hematopoietic and osteoblast cells after gamma-irradiation (Li
et al., 2012).
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To our knowledge, no miRNA that modulates RTP801 expres-
sion in a context of neurodegeneration has been described. In a
near future, miRNAs along with the long non-coding RNAs may
have a relevant impact in the regulation of RTP801 levels and
function.
RTP801 POST-TRANSLATIONAL REGULATION
Post-translational modifications like phosphorylation, acetyla-
tion, ubiquitination or myristoylation, have an important impact
in protein stability, function and cellular localization. Indeed, cel-
lular stresses can also affect turnover of many proteins, including
RTP801.
Apart from its rapid gene induction under stress, RTP801
proteostasis will also determine its stability, and therefore, its
regulatory function towards mTOR.
Related to that, RTP801 mRNA (Wang et al., 2003) and
RTP801 protein (Kimball et al., 2008; Katiyar et al., 2009;
Malagelada et al., 2010) half-lives are significantly short, revealing
that RTP801 is an extremely unstable protein with a fine-tuned
post-translational regulation.
One of the modifications that will lead to a rapid protein
turnover is ubiquitination. In fact, RTP801 is poly-ubiquitinated
and targeted for the ubiquitin-proteasome system (UPS; Katiyar
et al., 2009; Romaní-Aumedes et al., 2014).
To date, only three E3 ring ligases have been identified to
poly-ubiquitinate RTP801. The first one described was CUL4A-
DDB1-ROC1-β-TRCP E3 ligase complex. The complex ubiq-
uitinated RTP801 and targeted it for proteasomal degradation,
in a GSK3β-phosphorylation-dependent manner (Katiyar et al.,
2009).
The second E3 ubiquitin ligase for RTP801 was
HUWE1/MULE that modulated RTP801 protein levels although
this regulation seemed to be UPS-independent (Tan and Hagen,
2013).
So far, the role of both ligases in regulating RTP801 in neu-
rodegenerative disorders has not been elucidated.
In our recent work, we found that parkin RING E3 lig-
ase poly-ubiquitinates RTP801 to mediate its UPS degradation.
Based on the results obtained in cellular and animal models
and in samples from human parkin mutant carriers, we pro-
posed that RTP801 elevation due to parkin loss-of-function in
both parkin mutants and in idiopathic PD might contribute
importantly to neurodegeneration (Romaní-Aumedes et al.,
2014).
In a near future, other ligases will eventually be proved to
ubiquitinate RTP801, due to its central role in regulating mTOR.
RTP801 INACTIVATES mTOR VIA TUBEROUS SCLEROSIS
COMPLEX
Under stress conditions downregulation of mTOR activity caused
by hypoxia, energy stress or exposure to dopaminergic neurotox-
ins required the expression of RTP801 and an intact TSC1/TSC2
tumor suppressor complex (Brugarolas et al., 2004; Sofer et al.,
2005; Malagelada et al., 2006). Interestingly, despite the clear
necessity of the intact TSC1/2 complex for RTP801 to downreg-
ulate mTOR, RTP801 does not seem to interact physically with
either TSC1 or TSC2 (Vega-Rubin-de-Celis et al., 2010).
Tuberous sclerosis complex (TSC) is a heterodimer formed by
two proteins, the tuberous sclerosis tumor suppressors TSC1 and
TSC2. TSC2 has a catalytic function as a GTPase activating protein
(GAP), and it acts toward the small GTPase Rheb, an upstream
positive mTOR regulator (Inoki et al., 2003; Tee et al., 2003). TSC2
can be phosphorylated by several kinases in response to upstream
signals, and they will modify its regulation towards mTORC1
(reviewed in Ma and Blenis, 2009). Akt can phosphorylate TSC2
in response to growth factors (Inoki et al., 2002). This event is
thought to favor TSC2 binding to protein 14-3-3, instead to TSC1,
leading to TSC2 inhibition, to finally activate mTORC1 (Cai et al.,
2006).
Regarding the modulatory role of 14-3-3 towards TSC2,
DeYoung et al. (2008) proposed a molecular mechanism by
which RTP801 regulates TSC1/2-mTOR signaling involving 14-
3-3. Other studies also reported interaction between RTP801
and 14-3-3 proteins by co-immunoprecipitation experiments
(Favier et al., 2010; Hernández et al., 2011; Pieri et al.,
2014).
However, this RTP801 direct binding to 14-3-3 has been
questioned by others (Vega-Rubin-de-Celis et al., 2010). The
supposed 14-3-3 binding motif in RTP801 (133RLAYSEP139) is not
conserved within species and the crystallized RTP801 structure
analysis does not reveal any established mode for 14-3-3 binding.
Thus, the inhibitory mechanisms of RTP801 towards mTOR need
to be further investigated.
RTP801 UPREGULATION IN NEURODEGENERATION
The etiology of PD and many other neurodegenerative disorders
involves both environmental factors and genetic predisposition.
Indeed, exposure to several environmental toxins such as pesti-
cides and metals has been implicated in its pathogenesis (Migliore
and Coppede, 2009; Cannon and Greenamyre, 2011; Baltazar
et al., 2014).
Arsenic is a heavy metal that has been linked to neurotoxicity
and carcinogenesis in humans by a mechanism involving ROS
production (reviewed in Qian et al., 2003). Interestingly, arsenite
induced RTP801 transcription (Lin et al., 2005b).
Moreover, extensively used dithiocarbamate pesticides Maneb
(MB) and Mancozeb (MZ) induced DNA damage and elevated
RTP801 mRNA and protein expression (Cheng et al., 2014). The
toxicity mechanism of these pesticides has been linked to NF-
κB activation, revealing a cross-talk between RTP801 and NF-κB
(Cheng et al., 2014).
In line with this, RTP801 was also identified as an amyloid-
β-peptide (Aβ) responsive gene. Amyloid-beta is a neuro-
toxic molecule and the main component of senile plaques in
Alzheimer’s disease (AD; Kim et al., 2003).
Dopaminergic neurotoxins also upregulated RTP801 in cel-
lular and animal models. Specifically, RTP801 was upregulated
at both transcriptional and protein level in neuronal PC12 cells
treated with PD mimetic toxins 6-OHDA, MPP+ and rotenone,
and it was also induced in neurons of MPTP-treated mice and
in Substantia Nigra pars compacta (SNpc) degenerating neurons
of PD patients. Furthermore, RTP801 knockdown with short
hairpin RNAs (shRNAs) protected the cultures from PD mimetic
toxins (Malagelada et al., 2006).
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Ubiquitin-proteasome system deregulation has been impli-
cated in neurodegenerative disorders (Keller et al., 2000; Jana
et al., 2001; McNaught et al., 2003). Accumulations of misfolded
or aggregated proteins may hamper cellular functions and even-
tually lead to neuronal death (reviewed in Tanaka and Matsuda,
2014). RTP801 brief protein half-life suggests that UPS malfunc-
tion would affect RTP801 protein levels. Therefore it is logical to
suggest that a proper RTP801 degradation might be crucial for
neuron function and survival.
Thus, chronic and progressive RTP801 elevation could become
a hallmark of neurodegenerative disorders due to a combination
of stress-induced gene activation and UPS malfunction.
THE ROLE OF RTP801 IN NEURODEGENERATIVE DISORDERS
RTP801 behaves like many other stress-induced genes, where a
small increase is beneficial but a chronic and sustained increase
is detrimental for the neuron. Interestingly, since RTP801 is able
to inactivate protein translation, via mTOR, and survival, via Akt
(Malagelada et al., 2006, 2008, 2010), its pro-apoptotic role may
be relevant to other neurodegenerative diseases.
In PD, RTP801 elevation was initially identified in cellular
and animal models of the disease. These results were further
confirmed in nigral neurons from both idiopathic PD and mutant
parkin human brains, meaning that RTP801 may have a relevant
role in the disease itself (Malagelada et al., 2006).
Since RTP801 elevation is necessary and sufficient to trigger
neuronal death, it is logical to think that the upregulation in
the SN from PD human brains might be detrimental for the
nigral neurons. Interestingly RTP801 induces cell death through a
mechanism involving TSC1/2 and mTOR repression (Malagelada
et al., 2006). Indeed, RTP801 repression of mTOR led also to
the suppression of the phosphorylation of the neuronal survival
kinase Akt (Malagelada et al., 2008), reviewed in (Greene et al.,
2011). This negative regulation of Akt was also observed in nigral
neurons from PD human brains.
Based on these results, we proposed a mechanism to explain
RTP801 contribution to neurodegeneration in PD, where low
levels of RTP801 would help neurons to cope with stress, but if
this inactivation were sustained in time, it would impair neuronal
function and survival. At the latest stage, and when the critical
threshold of mTOR/Akt inactivation is surpassed, neuronal death
will occur (Malagelada et al., 2006, 2008; see Figure 1). This
proposed mechanism is supported by the observation of elevated
RTP801 and diminished Akt phosphorylation in nigral neurons
of PD brains (Malagelada et al., 2006; Romaní-Aumedes et al.,
2014).
To extend this working model, one possibility would be that at
early stages of many neurodegenerative disorders, RTP801 induc-
tion by cellular stresses would contribute to mTOR depression in
an attempt to preserve neuron function and viability. However,
at more advanced disease stages, when RTP801 upregulation
is prolonged in time, it can eventually promote neurodegen-
eration and neuronal death through mTOR and pro-survival
kinase Akt inactivation, as it has been proposed in the PD
studies.
In AD an elevation of both RTP801/REDD1 gene and pro-
tein was observed in lymphocytes from AD patients compared
to age-matched controls. Damjanac et al. (2009) showed that
Double-stranded RNA-dependent protein kinase (PKR), a cog-
nitive decline biomarker with an impairing protein translation
function, by phosphorylating p53, activated REDD1 gene tran-
scription. It could be interesting to explore whether this mech-
anism can be observed also in hippocampal neurons or in AD
murine models.
Recently, RT801 has been determined crucial for stress-
mediated synaptic loss and depressive behavior. Chronic unpre-
dictable stress increased RTP801 mRNA and protein levels in rat
prefrontal cortex (PFC). This RTP801 upregulation was coinci-
dent with a reduced phosphorylation of mTORC1/2 signaling
targets S6K, 4EBP1, and Akt. In agreement, RTP801 was elevated
in postmortem PFC of patients with major depressive disorder
compared to psychiatrically healthy controls. RTP801 knockout
mice were resilient to the synaptic and behavior deficits caused
by stress, while RTP801 overexpression in rat PFC was sufficient
to promote neuronal atrophy and depressive behavior (Ota et al.,
2014).
Further investigations are needed to elucidate the role of
RTP801 in many other neurological disorders. It will be interest-
ing to explore whether RTP801 levels are upregulated and whether
they correlate with the degree of mTOR/Akt repression. Also, it
will be important to determine whether RTP801 is promoting
neuron death through the same mechanism proposed as in PD
models.
RTP801 AS A POTENTIAL THERAPEUTIC TARGET
IN NEUROLOGICAL DISORDERS
Neurodegenerative disorders are characterized by neuronal death
of specific subpopulations, such as loss of SN dopaminergic neu-
rons in PD (reviewed in Dauer and Przedborski, 2003). However,
current PD therapies ameliorate symptoms but do not prevent
neuronal death. Thus, it is essential to investigate the mechanisms
that underlie neuronal death and identify targets involved in the
pathophysiology (reviewed in Levy et al., 2009). Based on several
studies, RTP801 could become one such potential therapeutic
target (Brafman et al., 2004; Malagelada et al., 2010; Tarazi et al.,
2014).
RTP801 promotes cell death by sequentially inactivating
mTOR and Akt (Malagelada et al., 2006, 2008). Thus, compounds
that can restrain RTP801 expression or modulate the mTOR/Akt
pathway may become therapeutic and delay neurodegeneration
and neuronal cell death in PD (reviewed in Tarazi et al., 2014).
One such compound is 8-methyl-6-phenoxy-2-(tetra-
hydropyran-4-ylamino)pyrido[2,3-d]pyrimidin-7-one (FLZ), a
synthetic squamoside derivative from a Chinese herb that
protected dopaminergic neurons from apoptosis triggered by
MPP+ and 6-OHDA (Zhang et al., 2007a,b). Interestingly, FLZ
neuroprotective actions in PD involved activation of Akt/mTOR
signaling pathway and inhibition of RTP801 expression (Bao
et al., 2012, 2014).
Another promising compound is rapamycin, an allosteric
inhibitor of some but not all mTOR activities. Rapamycin
conferred neuroprotection in both cellular and animal models of
PD (Tain et al., 2009; Dehay et al., 2010; Malagelada et al., 2010).
The results obtained support the hypothesis in which rapamycin
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FIGURE 1 | Schematic representation of the hypothesized regulation
of mTOR/Akt by RTP801 in neurons. In physiological conditions the
gene and the protein levels of RTP801 are low; mTOR is active and
promotes protein translation (mTORC1) and Akt phosphorylation at
Ser473 residue (mTORC2). These signals mediate neuronal survival (left
panel). However, when neurons are under stress, RTP801 is induced at
gene and protein levels, and promotes mTORC1 and mTORC2 inhibition
through TSC1-TSC2 complex and Rheb protein. These events result in
protein translation inhibition and prevent Akt phosphorylation at residues
Ser473 and, consequently, at Thr308. If this mTOR/Akt repression is
sustained over time neuron function is impaired and leads to neuron
death (right panel). Illustration by Olivares-Boldú L.
blocks RTP801 translation and, as a consequence, it mitigates
mTOR repression leading to Akt phosphorylation maintenance at
a site critical for its pro-survival activity (Malagelada et al., 2010).
In contrast, Torin 1, an inhibitor of all mTOR actions since it
blocks the ATP-binding site, was not protective and promoted Akt
dephosphorylation and neuron death. So, rapamycin protection
derives from its partial suppression of certain mTOR actions due
to its allosteric properties (Malagelada et al., 2010).
Nonetheless, further investigations are required to evaluate the
potential therapeutic role of these two agents in PD.
In animal and cellular models of cerebral ischemia, Ligustilide,
a major active agent of Radix Angelicae Sinensis, the root of
a chinese herb called Danngui, is neuroprotective by inhibiting
RTP801 expression, in addition to promote Erythropoietin tran-
scription via extracellular-signal-regulated kinases (ERK) signal-
ing pathway (Wu et al., 2011).
The most advanced example of RTP801 as a therapeutic target
is found in retinopathies. RTP801 has an important role in
the pathogenesis of retinopathies, since the absence of RTP801
expression in a mouse model attenuated the development of the
disease (Brafman et al., 2004). PF-04523655, a 19-ribonucleotide
siRNA designated to inhibit RTP801 transcription is currently in
clinical trials for retinopathy treatment (Lee et al., 2012; Nguyen
et al., 2012a,b; Rittenhouse et al., 2014).
In summary, RTP801 is one clear example of a protein that
is upregulated to cope with cellular stress although its sustained
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progressive elevation leads to neuron degeneration and death.
RTP801 progressive elevation and its inhibitory function towards
pro-survival kinases mTOR and Akt could explain its role in
several neurodegenerative diseases.
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